Positive association between triglyceride glucose index and arterial stiffness in hypertensive patients: the China H-type Hypertension Registry Study

Minghui Li
  Nanchang University Second Affiliated Hospital

Aihua Zhan
  zheyuan township hospital

Xiao Huang
  Nanchang University Second Affiliated Hospital

Lihua Hu
  Nanchang University Second Affiliated Hospital

Wei Zhou
  Nanchang University Second Affiliated Hospital

Tao Wang
  Nanchang University Second Affiliated Hospital

Lingjuan Zhu
  Nanchang University Second Affiliated Hospital

Huihui Bao
  Nanchang University Second Affiliated Hospital

Xiaoshu Cheng
  the Second Affiliated Hospital of Nanchang University

Original investigation

Keywords: Triglyceride glucose index, Brachial-ankle pulse wave velocity, Arterial stiffness, Hypertension

---

Abstract

Background: Data are limited on whether TyG index is an independent predictor of arterial stiffness in hypertensive patients. The purpose of this study was to assess the association between the TyG index and arterial stiffness, and examined whether there were effect modifiers, in hypertensive patients.

Methods: This study included 4718 hypertensive adults, a subset of the China H-type Hypertension Registry Study. The TyG index was calculated as ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. Arterial stiffness was determined by measuring brachial-ankle pulse wave velocity (baPWV).

Results: The overall mean TyG index was 8.84. Multivariate linear regression analyses showed that TyG index was independently and positively correlated with baPWV (β, 0.97; 95% confidence interval [CI] 0.78, 1.17). Consistently, Multiple logistic analyses showed a positive association between TyG index risk of elevated baPWV (> 75th percentile) (odds ratio [OR], 2.03; 95% CI 1.70, 2.41). Analyses using restricted cubic spline confirmed that the associations of TyG index with baPWV and elevated baPWV were linear. Subgroup analyses showed that stronger associations between TyG index and baPWV were detected in men (all P for interaction < 0.05).

Conclusion: TyG index was independently and positively correlated with baPWV and elevated baPWV among hypertensive patients, especially in men. The data suggest that TyG index may serve as a simple and effective tool for arterial stiffness risk assessment in daily clinical practice.

Background

Arterial stiffness, which is assessed by measuring pulse wave velocity (PWV), is recognized as an important predictor of cardiovascular events and mortality [1-3]. In clinical setting, Brachia-ankle pulse wave velocity (baPWV) measurement is widely used in large population studies, due to the advantages of high repeatability, simple operation and low time consumption, as well as it correlates with the stiffness of both central conduit and peripheral arteries. Most studies have revealed that elevated baPWV was associated with an increase in the risk of hypertension [4], diabetes [5], stroke [6], coronary artery calcification [7], cardiovascular disease (CVD) [3, 8], and mortality [9].

Insulin resistance (IR) can be considered an as important contributing factors in arterial stiffness progress [10] and the development of cardiovascular disease [11-13]. The hyperinsulinemic euglycemic clamp is the 'gold standard' for evaluating insulin resistance [14]. However, this method of assessing IR is time consuming, expensive, complex, and requires an intensive labor force. Thus, it is not ideal for routine clinical applications. Recently, triglyceride-glucose (TyG) index was suggested as a reliable and inexpensive surrogate biomarker of IR. The TyG index was calculated as ln[fasting triglycerides (mg/dL)×fasting glucose (mg/dL)/2] and shows a direct correlation with hyperinsulinemic euglycemic clamp [15, 16].

Several studies have demonstrated that higher levels of TyG index were associated with an increased risk of arterial stiffness [17-21]. However, most of the studies were conducted in a relatively healthy population. Of note, It is well establish that blood pressure is a significant risk factor for arterial stiffness. Little is known, about the role of TyG index, to assess the risk of arterial stiffness in hypertensive patients. Furthermore, few previous studies have comprehensively investigated potential modifiers of the association between TyG index and arterial stiffness risk. Therefore, we aimed to clarify whether TyG index could be used as an independent biomarker to predict the risk of arterial stiffness in hypertensive patients, and to examine any possible effect modifiers, using data from China H-type Hypertension Registry Study.

Methods

Participants

Data analyzed in this study was the baseline of the ongoing China H-type Hypertension Registry Study (Registration number: ChiCTR1800017274). The method of data collection and the exclusion criteria have been described previously [22]. Briefly, the study is a real-world, multicenter, observational study, conducted from Wuyuan, Jiangxi province of China, which conducted in July 2018. Eligible participants were adults aged 18 years and older who had hypertension, defined as seated, resting systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg at the screening, or who were on antihypertensive medications. The exclusion criteria included neurological abnormalities, unable to be followed-up according to the study protocol, or plans to relocate shortly, and the patients, who are not suitable for inclusion or for long-term follow-up as assessed by study physicians. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Institute of Biomedicine, Anhui Medical University. All participants provided written informed consent.

This study was restricted to a subset of participants with baPWV data available at baseline (n = 5233). Participants with an ankle-brachial index (ABI) < 0.90 (n = 124), taking statins (n = 181), or using glucose-lowering medications (n = 210), were excluded. Finally, 4718 subjects were analyzed. The selection process of study analytic sample was detailed description in Additional fle 1: Figure S1.

Clinical characteristics

According to a standard operating procedure, the baseline data of clinical examination and detailed questionnaires were collected by trained researchers. The standard questionnaire included age, sex, education, physical activity, current medication from pill bottles, previous medical diagnoses, smoking history, and drinking history. Anthropometric parameters indicators of the clinical examination included weight, height, waist circumference (WC), SBP, DBP. The body mass index (BMI) was calculated as weight (kg)/height (m^2). Blood pressure (BP) was measured using an electronic sphygmomanometers (Omron;

Dalian, China) with the subject in the sitting position after resting for 10 min, the average of the two measurements was used. .

Laboratory assays

Fasting venous blood samples were collected at the baseline, and were processed and analyzed at the clinical laboratory of the National Clinical Research Center for Kidney Disease, Guangzhou, China. Fasting plasma glucose (FPG), fasting lipids (serum total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), and triglycerides (TG)), serum homocysteine, serum uric acid (SUA), and creatinine were determined using automatic clinical analyzers (Beckman Coulter). Low-density lipoprotein cholesterol (LDL-C) was calculated according to the Friedewald formula. The TyG index was calculated as ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]. The formula for estimated glomerular filtration rate (eGFR) was used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [23].

BaPWV measurements

The ankle-brachial index (ABI) and baPWV were measured simultaneously with Omron Colin BP-203RPE III device (Omron Health Care, Kyoto, Japan). After having rest for more than 5 minutes in the supine position, 4 cuffs were wrapped around bilateral brachia and ankles and connected to a plethysmographic sensor and oscillometric pressure sensor. ABI was measured by the ankle SBP divided by the brachial SBP. Pressure waveforms were recorded using semiconductor pressure sensors to assess the transmission time between the initial rises in both the brachial and tibial arteries waves. The distance between sampling points of baPWV was estimated based on height. The baPWV was calculated using the formula (La-Lb)/Tba. La is the distance from the heart to the ankle, Lb is the distance from the heart to the brachium, and Tba is the time interval between the brachial and ankle waveforms. Two trained technicians were performed twice, and the average values of the left and right side assessments was used as a marker of arterial stiffness.

Statistical analysis

Data are presented as mean±standard deviation (SD) for continuous variables and as frequency (%) for categorical variables. The baseline characteristics of the different groups by TyG index quartiles were compared using ANOVA tests or Chi-square tests. The relationships between the TyG index and cardiometabolic risk factors were examined using Pearson's correlation. Because the predictive value of baPWV in cardiovascular events was not available. Elevated baPWV was defined as a value greater than 75th percentile of baPWV value in present study, which was greater than 20.02 m/s. The association of the TyG index with baPWV and elevated baPWV were evaluated using multivariate linear regression models (beta coefficient [β] and 95% confidence interval [CI]) and multivariate logistic regression models (odds ratio [OR] and 95% CI) with adjustment for major covariables in three models. Model 1: adjusted for age; Model 2: further adjusted for age, sex, education, BMI, WC, physical activity, current smoking, current drinking, SBP, DBP; Model 3: additionally adjusted for age, sex, education, BMI, WC, physical activity,

current smoking, current drinking, SBP, DBP, TC, SUA, serum homocysteine, HDL-C, LDL-C, eGFR, diabetes mellitus, antihypertensive drugs, antiplatelet drugs. Dose-response association of TyG index with baPWV and elevated baPWV were conducted using generalized additive model (GAM) and a fitted smoothing curve (penalized spline method). In addition, possible modifications on the association between TyG index and baPWV were also evaluated by stratified analyses and interaction testing.

All data analyzed were using the statistical package R (http://www. r-project.org) and Empower (R) (www.empowerstats.com; X&Y Solutions, Inc., Boston, MA). A 2-tailed P < 0.05 was considered to be statistically significant.

Results

Baseline characteristics

Data of 4718 participants were included in current analysis. The mean (SD) age of the participants was 64.41 (9.48) years; 2346 were men (49.72%). The mean baseline TyG index was 8.84 (0.63). Mean baPWV was 18.05 (3.85) m/s. The characteristics of the participants by TyG index quartiles are presented in Table 1. TyG index was inversely associated with age, serum homocysteine, HDL-C, and positively associated with BMI, WC, DBP, FPG, TC, TG, SUA, LDL-C, and eGFR. Moreover, participants with higher TyG index were significantly more likely to have diabetes mellitus, higher education levels, and using antihypertensive drugs. Participants with lower TyG index were significantly more likely to men, current smokers, and current drinkers.

Correlation between the TyG index and cardiometabolic risk factors

The results of pearson's correlation analysis for the relationship between the TyG index and cardiometabolic risk factors were described in Table 2. The TyG index was significantly correlated with BMI, WC, SBP, DBP,TC, HDL-C, LDL-C, and SUA after adjusted for age and sex (P < 0.05 for all).

Association of TyG index with baPWV and elevated baPWV

Overall, there were significant positive associations of TyG index with baPWV and the risk of elevated baPWV (Fig. 1a and 1b). Per 1 unit increment in TyG index, baPWV is changed in 0.97 m/s (95% CI 0.78, 1.17) according to the estimation from regression coefficients indication, and the odds ratios (OR) of the risk of elevated baPWV was 2.03 (95% CI 1.70, 2.41).

As shown in Table 3, after adjustment for different confounders, the positive association between TyG index and baPWV was found in all models (model 1-3). When TyG index was assessed as quartiles, in the fully adjusted model (model 3), the adjusted β of baPWV for participants in quartile 2, quartile 3, and quartile 4 were 0.55 (95% CI 0.29, 0.81), 0.83 (95% CI 0.54, 1.12), and 1.44 (95% CI 1.11, 1.78), respectively, compared with those in quartile 1 (P for trend < 0.001). Consistently, Table 4 presented the relative odds of having an elevated baPWV. Compared to participants in the lowest TyG index quartile, the adjusted OR for participants in the second, third and fourth quartiles were 1.43 (95% CI 1.13, 1.81), 1.96

(1.51, 2.53), and 3.03 (95% CI 2.26, 4.08), respectively. Also, P for trend in all models was significant (P for trend < 0.001), suggesting a dose-response relation between TyG index and baPWV and elevated baPWV.

Subgroup analyses by potential effect modifiers

We further performed stratified analyses to assess the effect of TyG index (per 1 unit increment) on baPWV in various subgroups. The association between TyG index and baPWV were consistent in the following subgroups: age (< 65 vs. ≥ 65 y; P-interaction = 0.10), BMI (< 25 vs. ≥ 25 kg/m^2; P-interaction = 0.14), physical activity (mild, moderate, vigorous; P-interaction = 0.69), current smoking (no vs. yes; P-interaction = 0.40), current alcohol drinking (no vs. yes; P-interaction = 0.97), diabetes mellitus (no vs. yes; P-interaction = 0.16), LDL-C (median, < 2.85 vs. ≥ 2.85 mmol/L; P-interaction = 0.42), and eGFR (< 60 vs. ≥ 60 mL/min per 1.73 m^2; P-interaction = 0.56).

However, there was a significant interaction between TyG index and sex on baPWV. A stronger positive association between TyG index and baPWV was found in men (β, 1.15; 95% CI 0.87, 1.44) compared with women (β, 0.73; 95% CI 0.46, 1.00; P-interaction = 0.02) (Fig. 2, Additional file 1: Figure S2). In addition, We further converted TyG index from a continuous variable to a categorical variable (quartiles) to explored the association of TyG index with baPWV and elevated baPWV in different gender. the magnitude of the effect of increase of the TyG index on baPWV and elevated baPWV were greater in men than in women (Additional file 1: Table S1).

Discussion

This study lends further support to the growing literature pointing to TyG index as an independent predictor of arterial stiffness, we demonstrated a significant positive association between TyG index and baPWV in hypertensive patients. Furthermore, our study expands the results of previously published studies by demonstrating that the positive relation of TyG index with baPWV was more pronounced in men.

Several studies have reported a positive association between TyG index and arterial stiffness [18–21, 24, 25]. Irace et al. [21] used data from two different cohorts found that the TyG index was strongly associated with carotid atherosclerosis, which was assessed by Doppler ultrasonography, and had better predictive value for IR than the homeostatic model assessment of insulin resistance (HOMA-IR). Won et al. [20] conducted a cross-sectional study of 2560 Korean subjects demonstrated that the TyG index is independently associated with arterial stiffness in a relatively healthy population. A recent study in a Northern Shanghai Study study of China also showed that an elevated TyG index was significantly associated with a higher risk of arterial stiffness and nephric microvascular damage after adjustment for traditional cardiovascular risk factors [19]. As we all know, blood pressure and vascular stiffness are interdependent. The propagation of increased blood pressure and fow pulsations may lead to vascular structure damaged and accelerate vascular stiffness. At the same time, arterial stiffness leads to increased arterial pulse pressure and pulsatile shear, contributing to hypertension [4, 26]. To date, there is

a particular lack of data on the role of TyG index on arterial stiffness in hypertensive patients. While in our study, we reported for the first time to examine the relationship between TyG index and arterial stiffness in hypertensive patients. Our analysis also clearly demonstrated that the TyG index was independently and positively associated with baPWV, even when the subjects included in the analysis were limited to those with high risk of arterial stiffness. Further confirmed the possibility that TyG index may serve as a novel and simple noninvasive biomarker to help evaluate the risk of arterial stiffness.

This study has also provide an another new insights, as a key finding to the sex-TyG index interaction. To our knowledge, only two studies have examined the association between TyG index and sex on arterial stiffness. Lee et al. [18] conducted a cross-sectional study of 3587 relatively healthy Korean adults, the results showed that the TyG index was independently associated with increased arterial stiffness, the OR for increased baPWV (> 75th percentile) for the highest and lowest quartiles of the TyG index was 2.92 (95% CI 1.92–4.44) in men and 1.84 (95% CI 1.15–2.96) in women. Consistent with the above results, our study also found that the magnitude of the effect of increase of the TyG index on the risk of elevated baPWV was greater in men than women (Additional file 1: Table S1). However, another study by Nakagomi et al. [27] examined the association between surrogate markers of insulin resistance and arterial stiffness in 2818 participants, this study found that the TyG index was associated with increased baPWV (> 75th percentile) and the associations were stronger in women than in men. The conflicting results might be attributed to the differences in age distribution. The mean age of the participants in Nakagomi et al. study was 38.8 years, while it was approximately 64.41 years in our study.

Although the exact mechanisms underlying the relationship of the TyG index with arterial stiffness is unclear, it may be linked to IR. IR is associated with hyperinsulinaemia, hyperglycaemia, dyslipidemia, hypertension and a proinflammatory state, as well as the effect of perturbed insulin signaling at the level of the intimal cells (endothelial cells, vascular smooth muscle cells, and macrophages), all of which predispose to arterial stiffness [28, 29]. The plausible biological explanation for the sex and TyG index interaction as seen in our current study may be due to the fact that men more likely to smoke and have central obesity (Additional file 1: Table S2). A study indicated that smokers have a high risk to developing an insulin resistance and hyperinsulinemia, compared with a matched group of non-smokers [30]. Moreover, a review also showed that central obesity can disrupt insulin signaling pathway, impair lipid metabolites, and increase non-esterified fatty acids concentrations, thereby causing arterial stiffness [31]. Further research is needed to examine the relationship between sex, IR and arterial stiffness.

The strengths of the present study were the inclusion of a large number of hypertensive participants, adjustment to minimize residual confounders, handled target independent variables as both continuous variables and categorical variables to reduce the contingency in the data analysis, and the subgroup analyses. However, several limitations should also be noted. First, this study was a cross-sectional design, which limits detection of causality. Second, the HOMA-IR of IR was not calculated because insulin levels were not measured in general health checkup. However, the direct correlation between the TyG index and HOMA-IR was well-established. Third, we did not collected detailed food intake information at baseline. As such, we could not examine the possible modifying effect of different foods on the TyG

index-arterial stiffness association. Fourth, all the participants included in this study were Chinese hypertensive patients. Therefore, it would be difficult to generalize to other populations.

Conclusion

In subjects with hypertension, we found a significant positive association between TyG index and baPWV, especially in men. The data suggest that TyG index may serve as a simple and effective tool for arterial stiffness risk assessment in daily clinical practice.

Abbreviations

PWV: pulse wave velocity; ba-PWV: brachial-ankle pulse wave velocity; CVD: cardiovascular disease; IR: insulin resistance; TyG: triglyceride glucose; SBP: systolic blood pressure; DBP: diastolic blood pressure; WC: waist circumference; BMI: body mass index; FPG: fasting plasma glucose; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; SUA: serum uric acid; LDL-C: low-density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; ABI: ankle−brachial index; BP: blood pressure; SD: standard deviation; CI: confidence interval; OR: odds ratio; β: beta coefficient; HOMA-IR: homeostasis model assessment of insulin resistance.

Declarations

Acknowledgements

Thanks to all the investigators and subjects who participated in the China Hypertension Registry Study.

Authors' contributions

The authors' responsibilities were as follows—MHL, AHZ, LHH, XH, HHB, and XSC: devised the study concept and designed the study; MHL, LHH, XH, WZ, TW, LJZ, HHB, and XSC: conducted the study; MHL, AHZ, LHH, and XH: conducted the data collection and analysis and drafted the manuscript; MHL, LHH, XH, WZ, TW, LJZ, HHB, and XSC: critically reviewed and revised the manuscript for important intellectual content; and all authors: read and approved the final manuscript. None of the other authors reported a conflict of interest related to the study.

Funding

This work was supported by the Science and Technology Innovation Platform Project of Jiangxi Province (Grant number: 20165BCD41005).

Availability of data and materials

The datasets used and/or analyzed in the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institute of Biomedicine, Anhui Medical University, Hefei, China. Informed written consent was obtained from all patients before their enrollment in this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

References

1. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, Boutouyrie P, Cameron J, Chen CH, Cruickshank JK et al: **Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects**. *J Am Coll Cardiol*. 2014; **63(7):636–646**.

2. Vlachopoulos C, Aznaouridis K, Stefanadis C: **Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis**. *J Am Coll Cardiol*. 2010; **55(13):1318–1327**.

3. Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y, Inoguchi T, Maeda Y, Kohara K, Tabara Y et al: **Brachial-Ankle Pulse Wave Velocity and the Risk Prediction of Cardiovascular Disease: An Individual Participant Data Meta-Analysis**. *Hypertension*. 2017; **69(6):1045–1052**.

4. Lee SJ, Avolio A, Seo DC, Kim BS, Kang JH, Lee MY, Sung KC: **Relationship Between Brachial-Ankle Pulse Wave Velocity and Incident Hypertension According to 2017 ACC/AHA High Blood Pressure Guidelines**. *J Am Heart Assoc*. 2019; **8(16):e13019**.

5. Won KB, Chang HJ, Kim HC, Jeon K, Lee H, Shin S, Cho IJ, Park SH, Lee SH, Jang Y: **Differential impact of metabolic syndrome on subclinical atherosclerosis according to the presence of diabetes**. *Cardiovasc Diabetol*. 2013; **12:41**.

6. Song Y, Xu B, Xu R, Tung R, Frank E, Tromble W, Fu T, Zhang W, Yu T, Zhang C et al: **Independent and Joint Effect of Brachial-Ankle Pulse Wave Velocity and Blood Pressure Control on Incident Stroke in Hypertensive Adults**. *Hypertension*. 2016; **68(1):46–53**.

7. Lee JY, Ryu S, Lee SH, Kim BJ, Kim BS, Kang JH, Cheong ES, Kim JY, Park JB, Sung KC: **Association between brachial-ankle pulse wave velocity and progression of coronary artery calcium: a prospective cohort study**. *Cardiovasc Diabetol*. 2015; **14:147**.

8. Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, Shido N, Tanaka N, Chikamori T, Yamashina A: **Brachial – ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome**. *Circ J*. 2005; **69(7):815–822**.

9. Sheng CS, Li Y, Li LH, Huang QF, Zeng WF, Kang YY, Zhang L, Liu M, Wei FF, Li GL et al: **Brachial-ankle pulse wave velocity as a predictor of mortality in elderly Chinese**. *Hypertension*. 2014; **64(5):1124–1130**.

10. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575–85.

11. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study. Diabetes Care. 2007;30(2):318–24.

12. Ma X, Dong L, Shao Q, Cheng Y, Lv S, Sun Y, Shen H, Wang Z, Zhou Y, Liu X. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):31.

13. Alizargar J, Bai CH, Hsieh NC, Wu SV. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc Diabetol. 2020;19(1):8.

14. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1):E15–26.

15. Unger G, Benozzi SF, Perruzza F, Pennacchiotti GL. Triglycerides and glucose index: a useful indicator of insulin resistance. Endocrinol Nutr. 2014;61(10):533–40.

16. Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.

17. Won KB, Park EJ, Han D, Lee JH, Choi SY, Chun EJ, Park SH, Han HW, Sung J, Jung HO. **et al**: Triglyceride glucose index is an independent predictor for the progression of coronary artery calcification in the absence of heavy coronary artery calcification at baseline. Cardiovasc Diabetol. 2020;19(1):34.

18. Lee SB, Ahn CW, Lee BK, Kang S, Nam JS, You JH, Kim MJ, Kim MK, Park JS. Association between triglyceride glucose index and arterial stiffness in Korean adults. Cardiovasc Diabetol. 2018;17(1):41.

19. Zhao S, Yu S, Chi C, Fan X, Tang J, Ji H, Teliewubai J, Zhang Y, Xu Y. Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study. Cardiovasc Diabetol. 2019;18(1):95.

20. Won KB, Park GM, Lee SE, Cho IJ, Kim HC, Lee BK, Chang HJ. Relationship of insulin resistance estimated by triglyceride glucose index to arterial stiffness. Lipids Health Dis. 2018;17(1):268.

21. Irace C, Carallo C, Scavelli FB. **De** Franceschi MS, Esposito T, Tripolino C, Gnasso A: Markers of insulin resistance and carotid atherosclerosis. A comparison of the homeostasis model assessment and triglyceride glucose index. Int J Clin Pract. 2013; 67(7):665–72.

22. Yu Y, Hu L, Huang X, Zhou W, Bao H, Cheng X. **BMI modifies the association between serum HDL cholesterol and stroke in a hypertensive population without atrial fibrillation**. J Endocrinol Invest.

2020.

23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AR, Feldman HI, Kusek JW, Eggers P. **Van** Lente F, Greene T **et al**: A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604–12.

24. Won KB, Park EJ, Han D, Lee JH, Choi SY, Chun EJ, Park SH, Han HW, Sung J, Jung HO. **et al**: Triglyceride glucose index is an independent predictor for the progression of coronary artery calcification in the absence of heavy coronary artery calcification at baseline. Cardiovasc Diabetol. 2020;19(1):34.

25. Poon AK, Meyer ML, Tanaka H, Selvin E, Pankow J, Zeng D, Loehr L, Knowles JW, Rosamond W, Heiss G. Association of insulin resistance, from mid-life to late-life, with aortic stiffness in late-life: the Atherosclerosis Risk in Communities Study. Cardiovasc Diabetol. 2020;19(1):11.

26. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308(9):875–81.

27. Nakagomi A, Sunami Y, Kawasaki Y, Fujisawa T, Kobayashi Y. Sex difference in the association between surrogate markers of insulin resistance and arterial stiffness. J Diabetes Complications. 2020;34:107442.

28. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575–85.

29. Imrie H, Abbas A, Kearney M. Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim Biophys Acta. 2010;1801(3):320–6.

30. Haj MD, Ezzaher A, Neffati F, Douki W, Gaha L, Najjar MF. Effect of cigarette smoking on insulin resistance risk. Ann Cardiol Angeiol (Paris). 2016;65(1):21–5.

31. Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci. 2015;11(3):463–82.

Tables

Table 1 Clinical characteristics of the study population according to TyG index

	Q1	Q2	Q3	Q4	P-value
	1180	1179	1179	1180	
rs)	66.93 ± 9.38	65.30 ± 9.48	63.86 ± 9.16	61.56 ± 9.07	<0.001
%)	765 (64.83)	588 (49.87)	493 (41.82)	500 (42.37)	<0.001
n, n (%)					0.001
school	1080 (91.53)	1079 (91.52)	1061 (89.99)	1030 (87.29)	
school	100 (8.47)	100 (8.48)	118 (10.01)	150 (12.71)	
m^2)	21.43 ± 3.04	22.71 ± 3.35	23.85 ± 3.31	24.95 ± 3.23	<0.001
	77.05 ± 8.85	80.74 ± 9.29	83.69 ± 8.85	86.78 ± 8.43	<0.001
activity, n (%)					0.283
	610 (51.69)	625 (53.01)	642 (54.45)	651 (55.17)	
ate	293 (24.83)	258 (21.88)	273 (23.16)	275 (23.31)	
us	277 (23.47)	296 (25.11)	264 (22.39)	254 (21.53)	
Hg)	147.10 ± 20.54	147.45 ± 19.01	147.26 ± 16.91	147.93 ± 17.39	0.717
Hg)	87.79 ± 14.53	88.85 ± 13.80	89.00 ± 10.59	91.05 ± 10.82	<0.001
ol/L)	5.36 ± 0.60	5.71 ± 0.71	6.05 ± 0.99	6.93 ± 2.09	<0.001
l/L)	4.58 ± 0.89	5.04 ± 0.93	5.39 ± 1.04	5.57 ± 1.23	<0.001
l/L)	0.80 ± 0.16	1.21 ± 0.18	1.71 ± 0.30	3.24 ± 1.65	<0.001
mol/L	407.56 ± 111.40	415.11 ± 117.35	432.64 ± 119.33	468.18 ± 125.63	<0.001
omocysteine, μmol/L	18.79 ± 11.99	19.34 ± 12.78	18.24 ± 11.70	17.72 ± 10.27	0.006
mmol/L)	1.63 ± 0.43	1.55 ± 0.39	1.47 ± 0.35	1.34 ± 0.36	<0.001
nmol/L)	2.43 ± 0.58	2.82 ± 0.64	3.16 ± 0.75	3.34 ± 0.84	<0.001
L/min per 1.73 m^2)	85.63 ± 19.62	86.00 ± 19.25	86.88 ± 18.28	87.77 ± 19.39	0.017
x	8.11 ± 0.23	8.59 ± 0.11	8.99 ± 0.12	9.68 ± 0.41	<0.001
smoking, n (%)	455 (38.56)	322 (27.31)	276 (23.41)	294 (24.92)	<0.001
drinking, n (%)	359 (30.42)	291 (24.68)	249 (21.12)	282 (23.90)	<0.001
mellitus, n (%)	26 (2.20)	37 (3.14)	47 (3.99)	122 (10.34)	<0.001
rtensive drugs, n (%)	657 (55.68)	710 (60.22)	721 (61.15)	731 (61.95)	0.009
let drugs, n (%)	18 (1.53)	29 (2.46)	29 (2.46)	20 (1.69)	0.226

Data are the mean± SD, or number (percentage).

BMI body mass index, *WC* waist circumference, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *FPG* fasting plasma glucose, *TC* total cholesterol, *TG* triglyceride, *SUA* serum uric acid, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *eGFR* estimated glomerular fltration rate, *TyG* triglyceride glucose, *ba-PWV* brachial to ankle pulse wave velocity.

Table 2 The correlation between TyG index and cardiometabolic risk factors after adjusted for age and sex

	r	P value
BMI (kg/m^2)	0.335	<0.001
WC (cm)	0.373	<0.001
SBP (mmHg)	0.030	0.042
DBP (mmHg)	0.055	<0.001
TC (mmol/L)	0.316	<0.001
HDL-C (mmol/L)	-0.284	<0.001
LDL-C (mmol/L)	0.395	<0.001
SUA (umol/L)	0.291	<0.001

TyG triglyceride glucose, *BMI* body mass index, *WC* waist circumference, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *TC* total cholesterol, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *SUA* serum uric acid.

Table 3 Association between TyG index and baPWV in different models

TyG index	baPWV, m/s, β (95%CI)		
	Model 1	Model 2	Model 3
Per 1 unit increase	0.86 (0.70, 1.02)	0.94 (0.78, 1.10)	0.97 (0.78, 1.17)
Quartiles			
Q1 (≥7.15, <8.40)	0.00	0.00	0.00
Q2 (≥8.40, <8.78)	0.56 (0.28, 0.84)	0.57 (0.31, 0.82)	0.55 (0.29, 0.81)
Q3 (≥8.78, <9.22)	0.72 (0.44, 1.00)	0.83 (0.56, 1.09)	0.83 (0.54, 1.12)
Q4 (≥9.22, ≤11.65)	1.37 (1.09, 1.65)	1.48 (1.21, 1.76)	1.44 (1.11, 1.78)
P for trend	0.021	<0.001	<0.001

Model 1: adjusted age

Model 2: adjusted for age, sex, education, BMI, WC, physical activity, current smoking, current drinking, SBP, DBP

Model 3: adjusted for age, sex, education, BMI, WC, physical activity, current smoking, current drinking, SBP, DBP, TC, SUA, serum homocysteine, HDL-C, LDL-C, eGFR, diabetes mellitus, antihypertensive drugs, antiplatelet drugs.

Abbreviations: *TyG* triglyceride glucose, *ba-PWV* brachial to ankle pulse wave velocity, CI confidence interval

Table 4 Association between TyG index and elevated baPWV in different models

TyG index	Elevated baPWV, OR (95%CI)		
	Model 1	Model 2	Model 3
Per 1 unit increase	1.77 (1.57, 1.99)	2.03 (1.76, 2.34)	2.03 (1.70, 2.41)
Quartiles			
Q1 (≥7.15, <8.40)	1.00	1.00	1.00
Q2 (≥8.40, <8.78)	1.33 (1.08, 1.63)	1.46 (1.16, 1.83)	1.43 (1.13, 1.81)
Q3 (≥8.78, <9.22)	1.63 (1.32, 2.00)	1.96 (1.55, 2.49)	1.96 (1.51, 2.53)
Q4 (≥9.22, ≤11.65)	2.47 (2.00, 3.05)	3.16 (2.46, 4.05)	3.03 (2.26, 4.08)
P for trend	<0.001	<0.001	<0.001

Model 1: adjusted age

Model 2: adjusted for age, sex, education, BMI, WC, physical activity, current smoking, current drinking, SBP, DBP

Model 3: adjusted for age, sex, education, BMI, WC, physical activity, current smoking, current drinking, SBP, DBP, TC, SUA, serum homocysteine, HDL-C, LDL-C, eGFR, diabetes mellitus, antihypertensive drugs, antiplatelet drugs.

Abbreviations: *TyG* triglyceride glucose, *ba-PWV* brachial to ankle pulse wave velocity, CI confidence interval

Figures

Figure 1

Dose−response relationship between TyG index and baPWV*. a TyG index and baPWV; b TyG index and elevated baPWV. *Adjusted for age, sex, education, BMI, WC, physical activity, current smoking, current drinking, SBP, DBP, TC, SUA, serum homocysteine, HDL-C, LDL-C, eGFR, diabetes mellitus, antihypertensive drugs, antiplatelet drugs. Abbreviations: TyG triglyceride glucose, ba-PWV brachial to ankle pulse wave velocity.

Subgroups	N	β (95%CI)	P for interaction
Age, years			0.10
<65	2206	0.65 (0.42, 0.87)	
≥65	2512	1.07 (0.72, 1.41)	
Sex			0.02
male	2346	1.15 (0.87, 1.44)	
female	2372	0.73 (0.46, 1.00)	
BMI, kg/m2			0.14
<25	3330	1.13 (0.88, 1.38)	
≥25	1386	0.63 (0.31, 0.95)	
Physical activity			0.69
mild	2528	1.10 (0.81, 1.39)	
moderate	1099	0.86 (0.49, 1.22)	
vigorous	1091	0.86 (0.46, 1.26)	
Current smoking			0.40
no	3371	0.78 (0.55, 1.01)	
yes	1347	1.27 (0.90, 1.64)	
Current drinking			0.97
no	3537	0.97 (0.74, 1.20)	
yes	1181	0.97 (0.60, 1.35)	
Diabetes mellitus			0.16
no	4486	0.94 (0.74, 1.15)	
yes	232	1.51 (0.79, 2.23)	
LDL-C, mmol/L			0.42
<2.85	2357	1.08 (0.81, 1.35)	
≥2.85	2361	0.90 (0.63, 1.18)	
eGFR, mL/min per 1.73 m2			0.56
<60	483	1.26 (0.44, 2.07)	
≥60	4235	0.97 (0.77, 1.18)	

Figure 2

Subgroup analyses of the effect of TyG index on baPWV. Adjusted for age, sex, education, BMI, WC, physical activity, current smoking, current drinking, SBP, DBP, TC, SUA, serum homocysteine, HDL-C, LDL-C, eGFR, diabetes mellitus, antihypertensive drugs, and antiplatelet drugs, if not be stratified. Abbreviations: TyG triglyceride glucose, ba-PWV brachial to ankle pulse wave velocity, BMI body mass index, LDL-C low-density lipoprotein cholesterol, eGFR estimated glomerular fltration rate, CI confidence interval.